Objective: To examine potential disease-modifying effects of statin drugs, we conducted a 12-month randomized, placebo-controlled clinical trial of simvastatin in cognitively normal adults using change in CSF Alzheimer disease biomarkers as primary outcome measure.
Elevated cholesterol levels and genetic variants in HMG-CoA reductase (the rate-limiting enzyme in cholesterol synthesis) are associated with altered risk of Alzheimer disease (AD). 1, 2 Treatment with cholesterol-lowering statin drugs is associated with decreased AD risk and neurofibrillary tangle burden. 1, 3 However, clinical efficacy trials of statins in patients with AD have been negative, 4 possibly because statins cannot reverse neuronal damage associated with progression to symptomatic AD. CSF biomarkers of AD (i.e., Ab 42 , total tau, and p-tau 181 ) change long before the onset of clinical dementia and may serve as surrogate markers of underlying disease processes. We previously demonstrated that 14 weeks of treatment with simvastatin (which penetrates the blood-brain barrier [BBB]), but not pravastatin (which does not penetrate BBB), was associated with a significant reduction of CSF p-tau 181 in cognitively normal adults with hypercholesterolemia. 5 In an attempt to confirm potential diseasemodifying effects of simvastatin, we conducted a randomized, placebo-controlled trial in cognitively normal participants using change in CSF AD biomarkers as the primary outcome measure. To address concerns of potential adverse effect of simvastatin on cognitive function, neuropsychological tests that are sensitive to subtle cognitive changes (e.g., attention, memory, learning, psychomotor speed, fine motor coordination) were performed.
METHODS Study design. Participants were 45-64 years of age, were statin-naive, and had normal cognition based on history, clinical examination, and neuropsychological testing. Persons with unstable medical or psychiatric conditions, head injury, or substance abuse were excluded, as were those whose cholesterol levels were sufficiently high as to require statin treatment (given the ethical concern of withholding statin treatment in those randomized to placebo).
Sixty potential participants were screened and 49 were randomized to treatment with simvastatin (n 5 26) or placebo (n 5 23). Twenty-five participants in the simvastatin group and 21 in the placebo group completed the 1-year study per protocol and were included in our primary analysis (figure 1). One participant in each group discontinued drug due to an adverse event, and one participant in the placebo group was lost to follow-up.
Interventions. Simvastatin was started at 20 mg/d and titrated over 2 weeks to a final dose of 40 mg/d. Placebo dosing was similarly titrated over 2 weeks.
Standard protocol approvals, registrations, and patient consents. The trial was registered on clinicaltrials.gov (NCT01142336), was approved by the University of Washington and VA Puget Sound Health Care System (VAPSHCS) institutional review boards, and all participants provided written informed consent prior to any study procedures.
Study outcomes. CSF and blood samples were collected in the morning after overnight fasting. CSF Ab 42 , total tau, and p-tau 181 were measured by the Knight Alzheimer's Disease Research Center at Washington University in St. Louis using the INNO-BIA AlzBio3 assay (Fujirebio, formerly Innogenetics, Ghent, Belgium), with longitudinal samples run on the same assay plate. Fasting serum lipids were analyzed in the VAPSHCS clinical laboratory. APOE (GenBank, M12529) genotype was determined by restriction digest methodology. Neuropsychological tests were performed at baseline and at end of study as safety measures.
Statistical analysis. Analysis of covariance (ANCOVA) was used to assess biomarker change from baseline, with concentration at end of study as the response variable. Predictor variables included concentration at baseline, treatment assignment, age, sex, and APOE e4 status (presence/absence of e4). Models for neuropsychological tests included education and Wechsler Test of Adult Reading scores as covariates. As a sensitivity analysis, we used linear mixed-effects models to include all participants who were randomized and had a baseline visit. To examine the potential modifying effect of sex, APOE e4 status, and baseline cholesterol levels, we included an interaction term for treatment assignment by each of these factors in the ANCOVA model for each biomarker.
RESULTS Demographics, APOE e4 status, and baseline serum analyte and CSF biomarker values were similar between participants randomized to the placebo and simvastatin groups (table e-1 at Neurology.org), except that baseline serum highdensity lipoprotein (HDL) was slightly lower in the simvastatin group. A similar pattern was seen in the primary analysis sample (data not shown).
Effect of simvastatin on CSF AD biomarkers. Change from baseline did not differ significantly between treatment groups for any of the CSF biomarkers by ANCOVA, after adjusting for age, sex, and presence of APOE e4 allele (figure 2), with p values of 0.53, 0.36, and 0.25 for CSF Ab 42 , total tau, and p-tau 181 , respectively. Results based on the linear mixed effects models that included all study participants were similar (data not shown). Gray area represents the 95% confidence interval for the slope.
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Safety. There were no increased reports of memory problems, anxiety, or depression (p . 0.05) or elevations of serum creatine phosphokinase or liver enzymes (all p . 0.05) in the simvastatin group compared to the placebo group (data not shown). There were no significant differences by treatment group in 12-month change for any of the 12 neuropsychological test scores after covariate adjustment (table e-2).
DISCUSSION Twelve months of treatment with simvastatin 40 mg/d did not change CSF Ab 42 , total tau, or p-tau 181 concentrations in cognitively normal participants with normal or mildly elevated cholesterol levels and did not impair cognitive function. We did not replicate our previous finding that 3 months of simvastatin treatment reduced CSF p-tau 181 in cognitively normal adults with hypercholesterolemia, even though the current study was 2 times larger, of longer duration (12 vs 3 months), and used placebo (rather than a non-brain-penetrant statin) as the control intervention. The lack of effect of simvastatin on p-tau 181 in the current study may reflect the relatively low serum cholesterol levels in our study participants, as decreases of CSF p-tau 181 were associated with both baseline LDL levels and decreases of serum LDL. Although the mechanism by which statins reduce tau phosphorylation is unclear, studies have shown that cholesterol modulates tau phosphorylation in cultured neurons 6 ; elevated serum cholesterol levels are associated with enhanced neuronal tau pathology in P301L human tau mice 7 ; and atorvastatin reverses hypercholesterolemiainduced increases in rat brain p-tau production. 8 Furthermore, high CSF cholesterol levels in humans are associated with elevated CSF p-tau 181 . 9 Consistent with our earlier study 5 and others, 10 simvastatin did not alter CSF concentrations of Ab 42 or total tau. A major limitation of this study is the small sample size; the null findings could be due to lack of power. This study was originally powered to detect an effect size of 0.6 with 80% power based on our pilot study, 5 assuming 50 participants per group would complete the 1-year study. Another limitation is that women are overrepresented in our sample. Nevertheless, that high serum LDL predicts simvastatin-related reductions in CSF p-tau 181 suggests that potential disease-modifying effects of simvastatin on CSF phospho-tau should be further investigated in a larger sample of persons with clinically significant hypercholesterolemia.
